Introduction
Methods
Study design and timeline
Symptom reporting
Depression
Impact on life functioning
Statistical analyses
Results
Cohort characteristics
Characteristic | Mean ± SD (range) |
---|---|
Age (years) | 48.9 ± 15.5 (20–75) |
Formal schooling (years) | 16.12 ± 2.37 (11–21) |
Income (dollars) | 139,833 ± 110,871 (27,000–500,000)a
|
Number of additional diagnoses | 1.33 ± 0.53 (0–5) |
Number of prescriptions | 1.0 ± 1.59 (0–6) |
N (%) | |
---|---|
Sex | |
Male | 35 (56) |
Female | 28 (44) |
Race | |
White, non-Hispanic | 61 (95) |
White, Hispanic | 1 (2) |
Other, non-Hispanic | 1 (2) |
Education | |
Some high school | 1 (2) |
High school graduate | 6 (9) |
Some college | 13 (21) |
College graduate | 20 (32) |
Graduate/professional | 23 (36) |
Characteristic | Mean ± SD (range) |
N (%) |
---|---|---|
Erythema migrans rash | ||
Size of primary rash (cm2) | 133.1 ± 125.1 (15–594) | |
Single | 43 (68) | |
Disseminated | 20 (32) | |
Physical exam abnormalities | ||
Fever ≥ 38.0°Ca
| 3 (5) | |
Lymphadenopathy | 9 (14) | |
Liver span | 5 (8) | |
Spleen tip | 2 (3) | |
Illness duration (days) | 7.9 ± 6.2 (1–35) | |
Seropositive based on two-tier algorithm | 25 (40) | |
Lymphocytes | ||
Absolute count, 103 (μL) | 1.3 ± 0.6 (0.3–3.4) | |
>1.10 × 103 (μL) | 24 (38) | |
Liver function testsb
| ||
AST (U/L) | 43.7 ± 62.1 (10–413) | |
ALT (U/L) | 51.5 ± 94.9 (10–704) | |
AST > 35 U/L or ALT > 40 U/L | 23 (37) |
Self-report on clinical exam | |||
---|---|---|---|
≥25% of sample | <25% of sample | ||
Symptom |
N (%) | Symptom |
N (%) |
Fatigue | 48 (76) | Nausea | 14 (22) |
Headache | 44 (70) | Irritability | 13 (21) |
Fever | 38 (60) | Visual sensitivity to light | 10 (16) |
Sweats | 38 (60) | Parasthesias | 10 (16) |
Chills | 38 (60) | Sore throat | 10 (16) |
Muscle pains | 34 (54) | Change in vision clarity | 8 (13) |
Joint pains | 30 (48) | Urination changes | 9 (14) |
Neck pain | 29 (46) | Diarrhea | 7 (11) |
Sleep disturbance | 26 (41) | Heart palpitations | 7 (11) |
Dizziness | 19 (30) | Tinnitus | 6 (10) |
Low back pain | 17 (27) | Loss of coordination | 6 (10) |
Difficulty concentrating | 15 (24) | Anxiety | 6 (10) |
Beck Depression Inventory II | |
---|---|
Mean ± SD (range) | |
Total score | 4.4 ± 4.3 (0–19) |
Temporal trends
Group differences
Instrument | PTLDS+ Pre-treatment | PTLDS− Pre-treatment | PTLDS+ Post-treatment | PTLDS− Post-treatment | ||||
---|---|---|---|---|---|---|---|---|
Mean (SD) | Median | Mean (SD) | Median | Mean (SD) | Median | Mean (SD) | Median | |
SF-36 | ||||||||
Physical Functioning | 47.39 (11.24) | 51.77 | 52.03 (8.72) | 55.98 | 49.03 (9.35) | 51.77 | 53.70 (5.14)* | 54.93 |
Role Physical | 44.61 (9.86) | 45.84 | 49.32 (9.42) | 51.96 | 40.81 (10.67) | 42.16 | 49.13 (8.87)*** | 51.96 |
Bodily Pain | 45.89 (13.20) | 48.18 | 48.86 (8.97) | 50.71 | 48.11 (12.45) | 53.25 | 52.87 (9.84) | 55.36 |
General Health | 52.50 (7.58) | 53.65 | 55.13 (6.25) | 55.74 | 51.79 (9.42) | 52.93 | 55.22 (5.84) | 55.32 |
Vitality | 48.03 (11.55) | 50.53 | 53.03 (10.56) | 55.21 | 45.22 (13.23) | 44.29 | 53.13 (10.94)* | 55.21 |
Social Functioning | 47.85 (11.09) | 51.40 | 50.31 (9.50) | 56.85 | 42.67 (12.18) | 45.94 | 50.28 (9.12)** | 56.85 |
Role Emotional | 50.83 (9.19) | 55.88 | 54.23 (4.97) | 55.88 | 48.49 (7.87) | 50.05 | 52.59 (8.58) | 55.88 |
Mental Health | 50.99 (9.15) | 52.82 | 54.87 (7.44) | 58.46 | 49.59 (6.97) | 50.01 | 54.85 (5.40)*** | 55.64 |